From Regional Patient Advocate Michal Rutkowski: It is very exciting to see the work of Dr Mariam Movsisyan from Allergology and Clinical Immunology Department of Yerevan State Medical University in Armenia. With the help of the Armenian Relief Fellow Alumni Association and an EU grant, ten HAE seminars were organized in four regions of the country. To understand more how rare and [...]
From Regional Patient Advocate Natasa Angjeleska: I have assisted a physician from Kosovo in finding a laboratory in North Macedonia and send patients for testing about HAE. This may help in diagnosing the first patients in this country. At the same time Dr. Shendevere Hasani, a pediatrician from Kosovo, had a presentation about HAE at the First Euroasian Pediatric Congress and [...]
From Regional Patient Advocate Natasa Angjeleska: Two new countries have been added to my region: Greece and Cyprus. I already have frequent and dynamic communication with patient representatives from Greece, as they were participating in the workshop in Skopje. I plan to communicate with the patient representatives from Cyprus in the coming period.
From Regional Patient Advocate Natasa Angjeleska: Two new countries have been added to my region: Greece and Cyprus. I already have frequent and dynamic communication with patient representatives from Greece, as they were participating in the workshop in Skopje. I plan to communicate with the patient representatives from Cyprus in the coming period.
From Regional Patient Advocate Maria Ferron: I am glad to announce that the first Regional Meeting for the Maghreb countries will be held 6-8 March 2020 in Algiers, Algeria.
Pharming Group N.V. has entered into a definitive agreement with Swedish Orphan Biovitrum AB (publ) (“Sobi”) to reacquire the commercial rights to Pharming’s product, Ruconest, in all remaining territories, which includes all remaining EU markets. Under the agreement, the license is being terminated with effect from 1 January 2020 in all 36 countries with a [...]
With our very best holiday regards we send you the fourth 2019 issue of the HAE International magazine Global Perspectives – your ultimate source of HAE information globally. This time you will, among many other items, find articles on these topics: A new global network of specialized treatment centers becomes a reality News from [...]
BioCryst Pharmaceuticals, Inc. has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral, once daily berotralstat (BCX7353) for the prevention of HAE attacks. “HAE patients are waiting for a safe, effective oral therapy to manage their disease and this NDA submission brings berotralstat an important step [...]
HAE International (HAEi) is excited to announce a new collaboration with GA2LEN— a nonprofit European based organization of leading clinical and research facilities in the field of allergy and asthma—to establish GA2LEN/HAEi ACARE (Angioedema Centers of Reference and Excellence). The joint venture with GA2LEN fulfills HAEi’s longstanding goal of establishing a world-wide network of accredited [...]
“We recently received Fast Track designation for KVD900, illustrating the high level of unmet need in the HAE community for efficacious and safe, orally-delivered therapies,” said Andrew Crockett, CEO of KalVista Pharmaceuticals, Inc. says in an operational update and financial results for the fiscal second quarter ended 31 October 2019. “Our Phase 2 clinical trial for KVD900 [...]
HAE International is a global non-profit network of member organizations dedicated to raising awareness of hereditary angioedema and improving the lives of people with HAE.
HAE International (HAEi)
10560 Main Street, Ste PS40
Fairfax City, VA 22030
United States of America
gro.ieah@ofni
HAE International (HAEi)
Vejlevej 16, 1.
8700 Horsens
Denmark
gro.ieah@ofni
